Brefeldin A ester derivatives and their preparation method and use

A technology of brefeldia and feldspar, which is applied in the direction of drug combinations, medical preparations containing active ingredients, organic active ingredients, etc., can solve the problems of poor water solubility, unsatisfactory, and inability to apply anti-tumor therapeutic reagents, etc. Achieve the effect of simple method and easy operation

Active Publication Date: 2014-05-14
ZHEJIANG UNIV OF TECH
View PDF2 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to its unsatisfactory pharmacokinetic properties (low bioavailability, poor water solubility

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Brefeldin A ester derivatives and their preparation method and use
  • Brefeldin A ester derivatives and their preparation method and use
  • Brefeldin A ester derivatives and their preparation method and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1: Preparation of 7-O-acetyl-BFA (I-1), 4,7-O-diacetyl-BFA (I-2)

[0035]

[0036] Add 10mL of anhydrous dichloromethane (10ml) to a 50mL round bottom flask with a magnetic stirring bar, then add BFA (100mg, 0.36mmol) and start stirring; then add acetic acid (45mg, 0.75mmol), EDC.HCl (1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride) (205mg, 108mmol), DMAP (4-dimethylaminopyridine) (22mg, 0.18mmol), at 40°C The reaction was heated for 24h to terminate the reaction. The reaction solution was diluted with 10ml of dichloromethane, washed with water (2×10ml), washed with saturated sodium chloride solution (2×10ml), the combined aqueous phase was extracted with ethyl acetate (1×30ml), the combined organic phase was anhydrous Dried over sodium sulfate, filtered, and concentrated to obtain a crude product, which was separated by thin-layer chromatography under the condition of developing solvent E / P=1:5 to obtain compound (I-1) (Rf=0.2, yield 42.50%) and ...

Embodiment 2

[0040] Example 2: Preparation of 7-O-(benzoic acid)acyl-BFA (I-3), 4,7-O-bis(benzoic acid)acyl-BFA (I-4)

[0041]

[0042] Add 10mL of anhydrous dichloromethane (10ml) to a 50mL round bottom flask with a magnetic stirring bar, then add BFA (100mg, 0.36mmol) and start stirring; then add benzoic acid (91.5mg, 0.75mmol), EDC .HCl (205mg, 108mmol), DMAP (22mg, 0.18mmol), heated at 40°C for 24h to terminate the reaction. The reaction solution was diluted with 10ml of dichloromethane, washed with water (2×10ml), washed with saturated sodium chloride solution (2×10ml), the combined aqueous phase was extracted with ethyl acetate (1×30ml), the combined organic phase was anhydrous Dried over sodium sulfate, filtered, and concentrated to obtain a crude product, which was separated by thin-layer chromatography under the condition of developing solvent E / P=1:5 to obtain compound (Ⅰ-3) (Rf=0.2, yield 46.7%) and Compound (I-4) (Rf=0.8 yield, 29.6%).

[0043] Compound Characterization: ...

Embodiment 3

[0046] Example 3: Preparation of 7-O-(p-fluorobenzoic acid)acyl-BFA (I-5), 4,7-O-bis(p-fluorobenzoic acid)acyl-BFA (I-6)

[0047]

[0048] Add 10mL of anhydrous dichloromethane (10ml) to a 50mL round bottom flask with a magnetic stirring bar, then add BFA (100mg, 0.36mmol) and start stirring; then add 4-fluorobenzoic acid (105mg, 0.75mmol) , EDC.HCl (205mg, 108mmol), DMAP (22mg, 0.18mmol), heated at 40°C for 24h to terminate the reaction. The reaction solution was diluted with 10ml of dichloromethane, washed with water (2×10ml), washed with saturated sodium chloride solution (2×10ml), the combined aqueous phase was extracted with ethyl acetate (1×30ml), the combined organic phase was anhydrous Dried over sodium sulfate, filtered, and concentrated to obtain a crude product, which was separated by thin-layer chromatography under the condition of developing solvent E / P=1:5 to obtain compound (Ⅰ-5) (Rf=0.2, yield 36.4%) and Compound (I-6) (Rf = 0.8, yield 20.0%).

[0049] Com...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides brefeldin A ester derivatives having antitumor activity and their preparation method and use. The brefeldin A ester derivatives have structures shown in the structural general formula (I). The brefeldin A ester derivatives have high effects on esophagus cancer, lung cancer, kidney cancer, colorectal cancer and prostatic cancer and have an in-vitro detection effective inhibition rate of 80%. The preparation method of the brefeldin A ester derivatives has simple processes and can be operated easily.

Description

(1) Technical field [0001] The invention relates to a class of brefeldin A ester derivatives with antitumor activity and its preparation and application. (2) Background technology [0002] Brefeldin A ((+) Brefeldin A BFA) is a natural macrolide antibiotic and a secondary metabolite of Ascomycetes, also known as clinomycin or ascodiosporum. In 1958, Singleton et al. first isolated it from the fermentation broth of Penicillium decumbens. In 1971, the complete configuration of BFA was determined by X-ray crystal structure analysis. Brefeldin A molecular formula C 16 h 24 o 4 , molecular weight 280Da, molecular structure contains 5 chiral centers, 2 double bonds, 1 five-membered carbon ring and 1 13-membered macrolide, the structure is as follows: [0003] [0004] Brefeldin A has a variety of biological activities, including antifungal, antiviral, antinematode, antimitotic, and it was found to have highly active inhibitory effects on various cancer cells (GI50=0.04μM)....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D313/00C07D409/12C07D409/14C07D495/04C07D405/14A61K31/365A61K31/4427A61K31/4188A61K31/625A61K31/381A61P35/00
CPCC07D313/00C07D405/14C07D409/12C07D409/14C07D495/04
Inventor 朱勍何秉踊郑裕国王亚军
Owner ZHEJIANG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap